Skip to main content

Table 1 Baseline demographic and clinical characteristics, by sex (n = 2736)

From: Social functioning outcomes in men and women receiving medication-assisted treatment for opioid use disorder

CharacteristicWomenMenp
Sex (n, % of total)1192, 44%1544, 56% 
Age in years (mean ± SD, min–max)37.58 ± 10.64, 18–6939.12 ± 11.14, 17–76< 0.001***
Type of MAT (n, % of total on Methadone)1008, 85%1313, 85%0.731
Type of MAT (n, % of total on Buprenorphine)184, 15%231, 15%0.731
Methadone dose; mg/day
(mean ± SD, min–max)
68.30 ± 40.13, 0–32073.23 ± 45.05, 2–4050.006**
Buprenorphine dose; mg/day
(mean ± SD, min–max)
12.31 ± 7.24, 1–4011.82 ± 6.74, 0–320.478
Years on MAT (median, IQR, min–max)2, 4.71, 0–402, 4.42, 0–330.432
New to MAT; < 1 year (n, % of total)436, 43%564, 43%0.904
Percentage of opioid-positive urine drug screens
(mean ± SD)
18.15% ± 26.4919.42% ± 27.880.228
Physical symptoms (mean score ± SD)16.50 ± 7.7013.62 ± 7.74< 0.001***
Psychological symptoms (mean score ± SD)14.01 ± 9.5511.37 ± 8.64< 0.001***
Unemployed (n, % of total)882, 74%902, 58%< 0.001***
Any crime (n, % of total)92, 8%177, 11%0.001**
Episodes of crime per month, in those who commit crime (median, IQR)4, 259, 880.032*
Any conflict (n, % of total)550, 46%533, 35%< 0.001***
Percentage of contact time spent in conflict, in those reporting conflict (median, IQR)8.45%, 26.10%7.69%, 20.20%0.596
  1. *p < 0.05
  2. **p < 0.01
  3. ***p < 0.001
  4. Min–max = minimum–maximum, MAT = medication-assisted treatment, SD = standard deviation, IQR = interquartile range